ACA
EPRX

Aptus Capital Advisors’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Aptus Capital Advisors’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$76K Buy
10,500
+500
+5% +$4.03K ﹤0.01% 1205
2025
Q4 		$75.5K Buy
+10,000
New +$61.6K ﹤0.01% 1227

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Aptus Capital Advisors's EPRX Position: Q1 2026 in Review

Aptus Capital Advisors increased its Eupraxia Pharmaceuticals (EPRX) stake by 5% in Q1 2026, buying an estimated $4.03K and bringing the position to 10,500 shares worth $76K. The position accounts for ﹤0.01% of the portfolio, ranked #1205.

Aptus Capital Advisors first reported a position in EPRX in Q4 2025 and has held it in 2 quarters since. 54 funds tracked by Wall St. Rank hold EPRX as of Q1 2026.

  • Aptus Capital Advisors held 10,500 shares of Eupraxia Pharmaceuticals worth $76K as of Q1 2026.
  • Aptus Capital Advisors bought 500 Eupraxia Pharmaceuticals shares in Q1 2026, an estimated $4.03K.
  • Eupraxia Pharmaceuticals made up ﹤0.01% of Aptus Capital Advisors's portfolio in Q1 2026, its #1205 holding.
  • Aptus Capital Advisors first reported a position in Eupraxia Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 54 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2026.

Based on Aptus Capital Advisors's 13F filing for Q1 2026, filed 11 May 2026.